Skip to main content
. Author manuscript; available in PMC: 2017 Jul 13.
Published in final edited form as: Biochemistry. 2016 Dec 22;56(1):22–32. doi: 10.1021/acs.biochem.6b00572

Figure 7.

Figure 7

(a) Drug sensitivity of WT and mutant (M766T) EGFR. Drug concentration from left to right: 0 μM, 0.01 μM, 0.1 μM, 1.0 μM, and 10.0 μM. Upper panel (lapatinib),44 middle panel (gefitinib),19 lower panel (erlotinib).43–45 (b) Structural binding mode of EGFR M766 with lapatinib/gefitinib/erloti nib.